The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, … [Read More...] about 8 drug delivery innovations you need to know
Main Content
Sponsored Content
Are You Prepared for the Upcoming Blanket No Change Certification Reporting Period? Learn more from Reed Tech
Listen to the recording of Reed Tech’s ‘Blanket No Change Certification webinar’ to learn about annual No Change Certification submission requirements for drug product listings and what steps are … [Read More...] about Are You Prepared for the Upcoming Blanket No Change Certification Reporting Period? Learn more from Reed Tech
Featured Posts
BriaCell Therapeutics closes $25M offering
BriaCell Therapeutics (NSDQ:BCTX) announced today that it closed an underwritten public offering worth $25 million. Berkeley, Calif.-based BriaCell offered more than 4.85 million common units comprised of one share of common stock and one warrant … [Read More...] about BriaCell Therapeutics closes $25M offering
8 drug delivery innovations you need to know
The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, … [Read More...] about 8 drug delivery innovations you need to know
Axonics acquires Contura and its Bulkamid bulking agent for $235M
Axonics (NSDQ: AXNX) announced today that it acquired Contura and its flagship Bulkamid product for up to $235 million. London-based Contura’s Bulkamid is a urethral bulking agent for women with stress urinary incontinence (SUI). It is a … [Read More...] about Axonics acquires Contura and its Bulkamid bulking agent for $235M
Lilly to add Welldoc app to future insulin pen
Eli Lilly (NYSE:LLY) and Welldoc announced a collaboration and licensing agreement to integrate Welldoc's software into Lilly's connected insulin pens, which are in development. Lilly and Welldoc will create a new version of Welldoc's BlueStar … [Read More...] about Lilly to add Welldoc app to future insulin pen
Kala Pharmaceuticals slides on missed Q4 projections
Kala Pharmaceuticals (NSDQ:KALA) shares dipped this morning on fourth-quarter results that came up short of the consensus forecast. The Watertown, Mass.-based company posted losses of -$31.1 million, or -55¢ per share, on sales of $2.2 million for … [Read More...] about Kala Pharmaceuticals slides on missed Q4 projections
Tandem Diabetes Care skyrockets after hours on Street-beating Q4
Tandem Diabetes Care (NSDQ:TNDM) shares soared after hours today on fourth-quarter results that topped the consensus forecast. Shares of TNDM were up 12.9% at $103.04 per share after the market closed. MassDevice's MedTech 100 Index — which … [Read More...] about Tandem Diabetes Care skyrockets after hours on Street-beating Q4
Insulet rises on Street-beating Q4 revenues
Insulet (NSDQ:PODD) shares rose before the market opened today on fourth-quarter results that beat the consensus revenue forecast. The Acton, Mass.-based wearable insulin delivery system developer posted losses of -$17.1 million, or -26¢ per … [Read More...] about Insulet rises on Street-beating Q4 revenues
B. Braun Medical appoints new CFO
B. Braun Medical announced today that it appointed James Allen as a senior VP and as the company’s chief financial officer. Allen, a veteran of more than 30 years in finance and management within multiple industries and disciplines, will replace … [Read More...] about B. Braun Medical appoints new CFO
Re-Vana Therapeutics appoints new COO, VP of R&D
Re-Vana Therapeutics announced today that it appointed Michael Nash as chief commercial officer and David Shima as VP of R&D. Belfast, Northern Ireland-based Re-Vana's two new executives are set to help the company develop its … [Read More...] about Re-Vana Therapeutics appoints new COO, VP of R&D
Pear Therapeutics touts cost-effectiveness of opioid use disorder treatment
Pear Therapeutics today touted analysis of its reSET-O therapeutic for opioid use disorder (OUD) that demonstrated cost-effectiveness. Boston-based Pear Therapeutics' reSET-O is the first and only FDA-authorized prescription digital therapeutic … [Read More...] about Pear Therapeutics touts cost-effectiveness of opioid use disorder treatment
In case you missed it
- Global wearable patch market growing at 10.6% rate
- AmacaThera raises $10.3M in oversubscribed Series A
- ForDoz enters manufacturing agreement with LipoMedix
- Acorda Therapeutics announces departure of business operations chief
- Evox Therapeutics completes $95.4M Series C
- Lyra Therapeutics names new chief medical officer
- NuTec, Epson combine to automate syringe production
- Retractable Technologies lands $54.2M federal contract for syringes
- BD wins Frost & Sullivan innovation award for Intevia autoinjector
- Report: Global syringes market set to reach $32.4B by 2027
- Dexcom Q4 earnings miss by a penny — but revenue up 23%
- United Therapeutics launches Remunity pump for Remodulin
- Surmodics rises on mixed-bag Q1
- Phillips-Medisize, Subcuject team on wearable osmotic bolus injector
- Dyve Biosciences appoints Camilla V. Simpson to its board
Clinical Trials
8 drug delivery innovations you need to know
The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the […]
Pear Therapeutics touts cost-effectiveness of opioid use disorder treatment
Pear Therapeutics today touted analysis of its reSET-O therapeutic for opioid use disorder (OUD) that demonstrated cost-effectiveness. Boston-based Pear Therapeutics’ reSET-O is the first and only FDA-authorized prescription digital therapeutic for treating OUD, according to a news release. The analysis, published in Postgraduate Medicine, highlighted that reSET-O and treatment-as-usual (which includes transmucosal buprenorphine, face-to-face counseling […]
Surmodics’ DCB shown non-inferior to Medtronic’s In.Pact Admiral
Surmodics (NSDQ:SRDX) announced data showing that its SurVeil drug-coated balloon is non-inferior to Medtronic’s In.Pact Admiral. Eden Prairie, Minn.-based Surmodics’ 12-month data from the Transcend clinical trial, presented at the Leipzig Interventional Course 2021 virtual event, revealed primary results that found the SurVeil DCB is non-inferior to In.Pact Admiral in both safety and efficacy while delivering […]
Johns Hopkins researchers tout medicine-delivering microdevices
Johns Hopkins researchers are touting microdevices that can latch onto intestinal mucosa and release drugs into the body. Led by engineering professor David Gracias and gastroenterologist Dr. Florin Selaru, the team of researchers and biomedical engineers designed and tested shape-changing microdevices that they say can mimic the way the parasitic hookworm affixes itself to an […]
Abbott touts Xience DES study results
A pair of studies of Abbott’s Xience drug-eluting stent showed no difference between shorter courses of treatment with dual antiplatelet therapy (DAPT) compared with 12 months of DAPT following implantation of the XIENCE drug-eluting stent (DES) in patients who are at a high risk of bleeding. Abbott presented the late-breaking data today at TCT Connect, the […]
